Cargando…

A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study

INTRODUCTION: Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Charytan, Chaim, Manllo-Karim, Roberto, Martin, Edouard R., Steer, Dylan, Bernardo, Marializa, Dua, Sohan L., Moustafa, Moustafa A., Saha, Gopal, Bradley, Charles, Eyassu, Meraf, Leong, Robert, Saikali, Khalil G., Liu, Cameron, Szczech, Lynda, Yu, Kin-Hung P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258588/ https://www.ncbi.nlm.nih.gov/pubmed/34307977 http://dx.doi.org/10.1016/j.ekir.2021.04.007

Ejemplares similares

Roxadustat for CKD-related Anemia in Non-dialysis Patients
por: Coyne, Daniel W., et al.
Publicado: (2020)

Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis
por: Provenzano, Robert, et al.
Publicado: (2020)

Retraction notice to “Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis.” Kidney Int Rep. 2021;6:613–623
por: Provenzano, Robert, et al.
Publicado: (2022)

Roxadustat: Not just for anemia
por: Zhu, Xiaoyu, et al.
Publicado: (2022)

The role of roxadustat in chronic kidney disease patients complicated with anemia
por: Liu, Jie, et al.
Publicado: (2023)

Effects of Roxadustat on the Anemia and Iron Metabolism of Patients Undergoing Peritoneal Dialysis
por: Hirai, Keiji, et al.
Publicado: (2021)

Iron Parameters in Patients Treated with Roxadustat for Anemia of Chronic Kidney Disease
por: Ganz, Tomas, et al.
Publicado: (2023)

Roxadustat for CKD Anemia – Starting the Jigsaw Puzzle, What Will the Finished Picture Show?
por: Winkelmayer, Wolfgang C., et al.
Publicado: (2021)

Efficacy of Roxadustat on anemia and residual renal function in patients new to peritoneal dialysis
por: Wu, Tong, et al.
Publicado: (2022)

Phase 3 Study of Roxadustat to Treat Anemia in Non–Dialysis-Dependant CKD
por: Akizawa, Tadao, et al.
Publicado: (2021)

Roxadustat for the treatment of anemia in patients with chronic kidney diseases: a meta-analysis
por: Zhang, Li, et al.
Publicado: (2021)

Roxadustat treatment for erythropoiesis-stimulating agent-hyporesponsive anemia in maintenance hemodialysis patients
por: Song, Jie, et al.
Publicado: (2023)

Pernicious Anemia Associated Cobalamin Deficiency and Thrombotic Microangiopathy: Case Report and Review of the Literature
por: Yousaf, Farhanah, et al.
Publicado: (2017)

Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients
por: Besarab, Anatole, et al.
Publicado: (2015)

Roxadustat for treatment of erythropoietin-hyporesponsive anemia in a hemodialysis patient: A case report
por: Yu, Wei-Hong, et al.
Publicado: (2020)

Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients
por: Akizawa, Tadao, et al.
Publicado: (2020)

The Efficacy and Safety of Roxadustat for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis
por: Wang, Lijun, et al.
Publicado: (2022)

Use of roxadustat (FG-4592) in ruxolitinib-treatment-related anemia of two myelofibrosis patients
por: Ding, Kai, et al.
Publicado: (2023)

Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis
por: Ichii, Mitsuru, et al.
Publicado: (2021)

Whether Prolyl Hydroxylase Blocker—Roxadustat—In the Treatment of Anemia in Patients with Chronic Kidney Disease Is the Future?
por: Grzeszczak, Władysław, et al.
Publicado: (2021)

Randomized Study on the Efficacy of Standard Versus Low Roxadustat Dose for Anemia in Patients on Peritoneal Dialysis
por: Yang, Zhikai, et al.
Publicado: (2021)

Efficacy and Mechanism of Roxadustat plus Oral Iron in the Treatment of Elderly Chronic Kidney Disease with Anemia
por: Liu, Bo, et al.
Publicado: (2022)

Correlation between blood concentration of roxadustat and clinical efficacy in patients with anemia of chronic kidney disease
por: Zhang, Yanjing, et al.
Publicado: (2023)

Clinical Pharmacokinetics and Pharmacodynamics of Roxadustat
por: Czock, David, et al.
Publicado: (2021)

Safety and Effectiveness of Roxadustat in Dialysis-Dependent Patients With Renal Anemia: A Hospital-Based Cohort Study
por: Moussa, Oumarou, et al.
Publicado: (2022)

Roxadustat for treatment of anemia in a cancer patient with end-stage renal disease: A case report
por: Zhou, Qiao-Qiao, et al.
Publicado: (2022)

Effects of roxadustat on anemia, iron metabolism, and lipid metabolism in patients with non-dialysis chronic kidney disease
por: Hirai, Keiji, et al.
Publicado: (2023)

Thyroid function analysis after roxadustat or erythropoietin treatment in patients with renal anemia: a cohort study
por: Zheng, Xiaomeng, et al.
Publicado: (2023)

Retracted: Efficacy and Mechanism of Roxadustat plus Oral Iron in the Treatment of Elderly Chronic Kidney Disease with Anemia
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

Roxadustat and thyroid-stimulating hormone suppression
por: Tokuyama, Atsuyuki, et al.
Publicado: (2021)

Safety and Efficacy of Roxadustat for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis and Trial Sequential Analysis
por: Liu, Chao, et al.
Publicado: (2021)

Roxadustat in treating anemia in dialysis patients (ROAD): protocol and rationale of a multicenter prospective observational cohort study
por: Zhang, Yaling, et al.
Publicado: (2021)

Label-free quantitative proteomic analysis of serum exosomes from patients of renal anemia: The Good and the Bad of Roxadustat
por: You, Xiaoe, et al.
Publicado: (2022)

Comparison of efficacy of roxadustat and erythropoietin for the treatment of renal anemia in patients with chronic kidney disease: a retrospective study
por: Jin, Chen, et al.
Publicado: (2022)

Effect of Roxadustat versus erythropoietin (EPO) for treating anemia in patients with diabetic kidney disease: a retrospective cohort study
por: Zhang, Lei, et al.
Publicado: (2022)

The efficacy and safety of roxadustat for anemia in patients with dialysis-dependent chronic kidney disease: a systematic review and meta-analysis
por: Zhou, Qiaoqiao, et al.
Publicado: (2023)

Effects of Roxadustat on Erythropoietin Production in the Rat Body
por: Yasuoka, Yukiko, et al.
Publicado: (2022)

Roxadustat: Do we know all the answers?
por: Li, Qiu-Yu, et al.
Publicado: (2023)

A Novel Choice to Correct Inflammation-Induced Anemia in CKD: Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat
por: Yan, Zhipeng, et al.
Publicado: (2020)

Beneficial effect of roxadustat on early posttransplant anemia and iron utilization in kidney transplant recipients: a retrospective comparative cohort study
por: Li, Hui, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h17k0bsj8por7e1bm51le4o8hl